# LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Study · id `cardio:ct-nct01380730` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01380730](<https://clinicaltrials.gov/study/NCT01380730>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01380730

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 631 participants.

## Technical summary

Registry record NCT01380730. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-01 (actual); primary completion 2012-04-05 (actual). Results posted on 2015-10-01.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 631 participants (enrolled count; ClinicalTrials.gov record NCT01380730, source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)
- Started: 2011-07-01 (actual) (ClinicalTrials.gov record NCT01380730, source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)
- Primary completion: 2012-04-05 (actual) (ClinicalTrials.gov record NCT01380730, source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)
- Completion: 2012-04-05 (actual) (ClinicalTrials.gov record NCT01380730, source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)
- Results first posted: 2015-10-01 (ClinicalTrials.gov record NCT01380730, source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)
- Countries: United States; Canada; Czechia; Denmark; Hungary (ClinicalTrials.gov record NCT01380730, source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01380730-2022-11-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
- Acronym: LAPLACE
- Condition: Hyperlipidemia
- Intervention (Biological): Evolocumab
- Intervention (Other): Placebo to Evolocumab
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial (`cardio:pubmed-23884353`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 93215bcbe9af51b40ccc4e3fe5a56a4499216032f770d2e5fe3d55982f85b92d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
